Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience

• Published in: Annals of hematology Vol. 102; no. 7; pp. 1907 - 1914
• Main Authors: Duda, Katarzyna, Wieczorkiewicz-Kabut, Agata, Koclęga, Anna, Zielińska, Patrycja, Woźniczka, Krzysztof, Krzemień, Helena, Armatys, Anna, Helbig, Grzegorz
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2023; Springer Nature B.V
• Subjects: Graft versus host disease; Hematology; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Stem cells; Transplants & implants; Allogeneic stem cell transplantation; Complications; Acute myeloid leukemia; Elderly; Outcome
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-023-05226-1

The incidence of AML increases with age. The implementation of reduced intensity conditioning and progress in supportive care enabled to perform allo-HSCT in elderly patients. The main objective of the study was to assess the safety and efficacy of allotransplantation in elderly AML.Forty nine patients (33 males) at median age of 68 years were identified. Data on patients’ and transplant’s related variables were retrieved from our local transplant registry. Most patients (65%) were transplanted from 10/10-HLA or 9/10-HLA matched unrelated donor, seven patients (14%) received stem cells from matched related donor and ten patients (20%) from haploidentical donor. All patients received reduced-intensity conditioning (RIC). Peripheral blood was a source of stem cells in all patients except one (98%). Acute GVHD developed in 22 patients (44%) with 5 individuals presenting grade III-IV. CMV reactivation was demonstrated in 19 patients (39%) till day + 100. In total, 22 patients (45%) have died. The main causes of death included infectious complications ( n  = 9), relapse with subsequent chemotherapy resistance ( n  = 7), steroid-resistant GvHD ( n  = 4) and other causes ( n  = 2). Twenty-seven patients (55%) were alive at the last contact, presented full donor chimerism and remained in the complete remission. The probability of OS and relapse-free survival (RFS) were 57% and 81% at 2 years, respectively. Older donor age showed negative impact on relapse. CMV reactivation, the severity of acute graft versus host disease and older donor age negatively influenced survival. Allo-HSCT remains a safe, feasible and effective procedure for elderly AML patients.